InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,648.40
(
1.01%
)
US TECH 100
19,050.40
(
1.19%
)
Dow Jones
41,563.08
(
0.55%
)
Brent Oil
77.34
(
0.19%
)
Bitcoin
59,192.67
(
0.12%
)
Post# of 253010
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120354
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 63998

Thursday, 07/24/2008 12:33:56 PM

Thursday, July 24, 2008 12:33:56 PM

Post# of 253010
NUVO NU172 notes from 2Q08 CC:

CEO Ted Love said NU172 has several benefits vs other anticoagulants for the CABG and dialysis settings: ability to act in stagnant blood, rapid on/off without an antidote, and lack of renal clearance (especially important in dialysis setting).

NU172 is in phase-1b (#msg-29771841).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up